Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | DAO | P14920 | 1/20 | 1.00 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 1.00 |
| ▸ | CES2 | O00748 | 3/20 | 0.78 |
| ▸ | CES1 | P23141 | 3/20 | 0.78 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA3 | P07451 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | CA6 | P23280 | 2/20 | 0.58 |
| ▸ | CA5A | P35218 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL4591761 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL149318 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL9751726 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL407365 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL137419 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL975929 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL11602198 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL3966600 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL7719037 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL2458489 | 1.00 | TSHR (1.00) | TSHRDAONAPRTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720889-B1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LTD (AU) | 2014-11-26 | — | — | EP | disclosed |
| US-8173606-B2 | Sulfated oligosaccharide derivatives | PROGEN PHARMACEUTICALS LIMITED (AU) | 2012-05-08 | — | — | US | disclosed |
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LIMITED (AU) | 2011-06-02 | — | — | US | disclosed |
| US-7875592-B2 | inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease | PROGEN PHARMACEUTICALS LIMITED (AU) | 2011-01-25 | — | — | US | disclosed |
| EP-1720889-A4 | SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LTD (AU) | 2008-03-19 | — | — | EP | disclosed |
| US-20070185037-A1 | Sulfated oligosaccharide derivatives | PROGEN INDUSTRIES LIMITED (AU) | 2007-08-09 | — | — | US | disclosed |
| EP-1720889-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | Progen Industries Limited (AU) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085264-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN INDUSTRIES LIMITED (AU) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185037-A1 | Sulfated oligosaccharide derivatives | HPSE, APOB, LIPG | TSHR 2610/4885DAO 2287/4885NAPRT 1043/4885 |
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | HPSE, APOB, LIPG | TSHR 2610/4885DAO 2287/4885NAPRT 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.